glp-1 obesity drug news october 9 2025 Alarming rise in weight loss overdoses GLP‑1 real‑world data for obesity:

A Danish study examining 424,152 persons with type 2 diabetes found patients exposed to weekly semaglutide had 2.19 times higher NAION risk, with Denmarks annual first-time NAION cases rising from 67.6 to 148 since Ozempics 2018 introduction

Recent lab work If you have had blood work done within the past 3 to 6 months, please bring a copy or have them sent over

S., Amaro, A., et al

Does the concentration affect how well semaglutide works

The ~15% weight loss observed with semaglutide approaches the 2030% weight loss achieved through bariatric surgery

Heterogeneity in the analyses vs active comparators could be attributed to differences in efficacy between the two GLP-1 RAs comparators (dulaglutide and semaglutide) or to differences in background glucose-lowering therapy between the two trials with basal insulin